Soft Tissue Sarcoma Market Research Report-Forecast till 2030

Soft Tissue Sarcoma Market Research Report – By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy), By Disease Type (Local, Regional, Metastatic Sarcoma), By Distribution Channel, By End User-Forecast till 2030

ID: MRFR/Pharma/3862-HCR | February 2021 | Region: Global | 90 pages         

Soft Tissue Sarcoma Market

Soft tissue sarcoma is a type of cancer that develops from tissues such as nerves, muscles, fats, blood vessels and deep skin tissues

Segmentation

By Treatment Targeted Therapy Chemotherapy Anti-Angiogenesis Drugs Radiation Therapy
By Disease Type Local Regional Metastatic Sarcoma

Key Players

  • GlaxoSmithKline plc (U.K)
  • Eli Lilly and Company (U.S.)
  • Pfizer
  • Inc. (U.S.)
  • Bristol-Myers Squibb (U.S.)
  • F. Hoffmann-La Roche AG (Genentech) (Switzerland)
  • Johnson & Johnson Services Inc. (U.S.)

Drivers

  • High incidence rate of soft tissue sarcomas
  • Increase in awareness about soft tissue sarcoma market
  • Rise in focus on healthcare
Speak to Analyst Request a Free Sample

Soft Tissue Sarcoma Market Scenario


Soft tissue sarcoma is a type of cancer that develops from tissues such as nerves, muscles, fats, blood vessels and deep skin tissues. Generally occuring in the muscles, tissues, and blood vessels that protect, support and surround the organs. Moreover, it is not categorized as tumor, but can be life-threatening if the cancer spreads to other parts of the body. There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma, and others.

Currently, there are very few products approved for the treatment of soft tissue sarcoma. For instance, in October 2016, U.S. Food and Drug Administration issued an accelerated approval notice for Eli Lilly and Company’s drug Lartruvo (Olaratumab) with Doxorubicin to treat certain types soft tissue carcinoma. Some of the drugs used for the treatment of soft tissue sarcoma include trabectedin (yondelis), sunitinib (sutent), sirolimus (rapamune), and doxorubicin (adriamycin), bevacizumab (avastin), and others.

Increase in the incidence and prevalence of different types of cancers, rising cases of soft tissue sarcoma, increasing R&D activities on drugs and other therapies, patent expiry of branded drugs, are some of the factors fuelling the growth of the soft tissue sarcoma market over the forecast period. However, stringent regulatory guidelines, adverse side effects of the treatment, and high cost for the radiotherapy and chemotherapy may hinder the growth of soft tissue sarcoma treatment market over the forecast period.

The methods for diagnosis of soft tissue sarcoma include some physical examination such as X-ray imaging, CT scan, MRI, ultrasound, PET scan and a biopsy. Such examinations in conjugation with other tests are important to plan a suitable treatment method for this condition.

The Global Soft Tissue Sarcoma Market is expected to grow at a CAGR of approximately 8.90% during the forecast period 2020-2030.

Soft Tissue Sarcoma Market Segmentation

The soft tissue sarcoma market is segmented on the basis of treatment, disease type, distribution channel, and end-users.

On the basis of the treatment type, the soft tissue sarcoma treatment market is segmented into targeted therapy, chemotherapy, anti-angiogenesis drugs, radiation therapy. Furthermore, the radiation therapy is subcatergorized into internal radiation therapy and external radiation therapy.

On the basis of the disease type, soft tissue sarcoma treatment market is segmented into local sarcoma, regional sarcoma, and metastatic sarcoma

On the basis of the distribution channel, soft tissue sarcoma treatment market is segmented into hospital pharmacies, retail pharmacies and others.

On the basis of the end user, the global soft tissue sarcoma treatment market has been segmented into hospitals, oncology centers, and long term care centers.

Soft Tissue Sarcoma Market- Key Players

Some of key the players in the global soft tissue sarcoma market are GlaxoSmithKline plc (U.K), Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Celgene Corporation (U.S.) and others.

Various key players are active in the soft tissue sarcoma treatment market in terms of product launches, research, and development activities. For instance, in 2012, Threshold Pharmaceuticals Inc. signed a global license agreement for Evofosfamide, which is the most advanced first-line drug for soft tissue sarcoma with Merck KGaA. GSK’s Votrient (pazopanib) is approved for second-line treatment, and another drug Aldoxorubicin is approved as first-line drug for the treatment of soft tissue sarcoma. Currently, doxorubicin is commonly used for the treatment of soft tissue sarcoma.

Research Methodology Soft Tissue Sarcoma Market Sources: Annual reports, Press release, White paper, and Company presentation

Soft Tissue Sarcoma Market Regional Analysis

The global soft tissue sarcoma market consists of countries namely America, Europe, Asia Pacific, and the Middle East & Africa.

The Americas soft tissue sarcoma market is projected to hold the largest share of the global soft tissue sarcoma market. Moreover, North America dominated the overall market in terms of revenue in 2016. According to American Cancer Society, approximately 12,390 people in 2016 were believed to suffer from  soft tissue sarcoma and related cancer. High incidence rate of soft tissue sarcomas, increase in awareness about this condition, rise in focus on healthcare, and well-established healthcare infrastructure are some of the factors driving the market in North America.

Europe holds a key share in soft tissue sarcoma treatment market attributed to change in lifestyle, increase in R&D activities for the development of new drugs. The European soft tissue sarcoma market is expected to have a tremendous growth during the forecast period.

The market in Asia Pacific is estimated to expand at a high CAGR during the forecast period, led by an increase in government spending on healthcare services in India and China. The Middle East & Africa is projected to expand during the forecast period, owing to the rise in investments by market players and increase in prevalence of soft tissue sarcomas.

Intended Audience


  • Soft Tissue Sarcoma Drug Suppliers

  • Soft Tissue Sarcoma Drug Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities



Report Scope:
Report Attribute/Metric Details
  Market Size   2030 : Significant Value
  CAGR   2020-2030: 8.90%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, distribution channel, and end-users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GlaxoSmithKline plc (U.K), Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Celgene Corporation (U.S.) and others
  Key Market Opportunities   Research and Development
  Key Market Drivers

  • High incidence rate of soft tissue sarcomas
  • Increase in awareness about soft tissue sarcoma market
  • Rise in focus on healthcare


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The outlook of the global soft tissue sarcoma market looks extremely promising.

    The global soft tissue sarcoma market is projected to grow at approximately 8.90% CAGR during forecast period (2020-2030).

    North America holds the largest share in the global soft tissue sarcoma market followed by Europe and Asia Pacific, respectively.

    Eli Lilly and Company (US), GlaxoSmithKline plc. (UK), Pfizer, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Bristol-Myers Squibb (US), Johnson & Johnson Services, Inc. (US), Celgene Corporation (US), and Teva Pharmaceutical Industries Ltd (Israel), are some of the major players operating in the soft tissue sarcoma market.